Q-omics provides the consensus-scored PRR4 profile across patient tissues and cancer cell-line models. PRR4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRR4 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PRR4 RNA expression shows 20,519 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where PRR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR4 survival associations across molecular data types. PRR4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR4 RNA expression–survival associations across cancer types. High PRR4 expression shows unfavorable associations in KIRC, UVM, COAD, KIRP and ACC, but favorable associations in STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRR4 RNA expression.
This table summarizes PRR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR4 shows lower tumor expression in HNSC and BRCA and higher tumor expression in KIRC, READ, LIHC and COAD. The KIRC box plot shows higher PRR4 RNA expression in tumor versus normal tissue (log2 FC = +0.148, t-test p < 0.001).
This table shows molecular features associated with PRR4 in patient tissues and cancer cell lines. In patient samples, PRR4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
